FDA Grants Approval for Leucovorin Calcium ANDA072734 by Hikma
The FDA has granted approval for Hikma's abbreviated new drug application for Leucovorin Calcium.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Supportive Care
Company: Hikma
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hikma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Hikma's ANDA for Leucovorin Calcium introduces a new competitor in the oncology supportive care market. This could lead to pricing pressures and shifts in market share, necessitating close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Hikma and competitors.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.